Vertex(VRTX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024. For the full year 2025, total revenue was $12 billion, reflecting a 9% increase versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated a full year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, demonstrating continued momentum in patient initiations [34][35] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with substantial growth in quarterly prescriptions since its launch [34] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [22] - In Europe, reimbursement for ALYFTREK has been secured in key countries, including the UK, Germany, and Italy, expanding access to CFTR modulators [22][23] - CASGEVY's reimbursement agreements in the U.S. have reached approximately 90% access for both Medicaid and commercial patients [23] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is emerging as a key growth engine, with povetacicept positioned to address significant unmet needs in IgA nephropathy and membranous nephropathy [10][29] - The company is focused on commercial execution and innovation to drive sustained growth across multiple serious disease areas [6][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on significant opportunities and drive sustained growth through commercial execution and innovation [6][40] - The guidance for 2026 anticipates total company revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept, with expectations for expedited regulatory review [11] - The company is committed to maintaining comprehensive patient support programs to facilitate access to its therapies [29] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to povetacicept - Management indicated that while BAFF/APRIL inhibitors may decrease IgG levels, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [42][44] Question: Guidance details for CF component and ALYFTREK - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, but did not break down specifics for ALYFTREK versus other products [49][51] Question: Payer access and reimbursement for povetacicept - Management reported positive engagements with payers, having conducted 74 meetings covering over 210 million lives, indicating strong interest in the upcoming products [55][60] Question: Expected results on proteinuria for povetacicept - Management emphasized the importance of magnitude of proteinuria response, referencing a 56% reduction seen in the RUBY-3 study as a benchmark for expected outcomes [62][64] Question: Differentiation of povetacicept in generalized myasthenia gravis - Management highlighted the engineered profile of povetacicept, which offers better potency and pharmacokinetics compared to existing treatments, positioning it as a promising option in a crowded market [68][70]